CSIMarket
 


Halozyme Therapeutics Inc   (HALO)
Other Ticker:  
 

Halozyme Therapeutics Inc 's Leverage Ratio

HALO's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 0.36%, Leverage Ratio fell to 19.68, above the Halozyme Therapeutics Inc 's average Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry in the forth quarter 2023, 16 other companies have achieved lower Leverage Ratio than Halozyme Therapeutics Inc in the IV Quarter 2023. While Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 1304, from total ranking in the third quarter 2023 at 3304 .

Explain Leverage Ratio?
Who are HALO Customers?
What are HALO´s Total Liabilities?


HALO Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change -50.64 % 156.91 % -48.48 % -74.7 % -13.79 %
Y / Y Total Liabilities Change 1.6 % 2.5 % 11.5 % 81.11 % 78.91 %
Leverage Ratio MRQ 19.68 6.6 10.99 24.81 9.56
HALO's Total Ranking # 1304 # 3304 # 2731 # 4033 # 3138
Seq. Equity Change -66.37 % 64.98 % 129.36 % -61.22 % 75.07 %
Seq. Total Liabilities Change 0.36 % -0.96 % 1.58 % 0.62 % 1.26 %



Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 17
Healthcare Sector # 163
Overall Market # 1304


Leverage Ratio Statistics
High Average Low
28.85 5.43 0.5
(Jun 30 2016)   (Sep 30 2019)




Financial Statements
Halozyme Therapeutics Inc 's Equity $ 84 Millions Visit HALO's Balance sheet
Halozyme Therapeutics Inc 's Total Liabilities $ 1,649 Millions Visit HALO's Balance sheet
Source of HALO's Sales Visit HALO's Sales by Geography


Cumulative Halozyme Therapeutics Inc 's Leverage Ratio

HALO's Leverage Ratio for the trailling 12 Months

HALO Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth -50.64 % 156.91 % -48.48 % -74.7 % -13.79 %
Y / Y Total Liabilities TTM Growth 1.6 % 2.5 % 11.5 % 81.11 % 78.91 %
Leverage Ratio TTM 11.98 10.32 13.48 10.14 6.85
Total Ranking TTM # 36 # 3389 # 233 # 3779 # 3044
Seq. Equity TTM Growth -66.37 % 64.98 % 129.36 % -61.22 % 75.07 %
Seq. Total Liabilities TTM Growth 0.36 % -0.96 % 1.58 % 0.62 % 1.26 %


On the trailing twelve months basis Due to the net new borrowings of 0.36% during the trailing twelve months finishing in the IV Quarter 2023, cumulativeLeverage Ratio improved to 11.98, above the Halozyme Therapeutics Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 2, during the past 12 months, other companies have achieved lower Leverage Ratio than Halozyme Therapeutics Inc . While Leverage Ratio total ranking has improved so far to 36, from total ranking in previous 12 month period at 3389.

Explain Leverage Ratio?
Who are HALO Customers?
What are HALO´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 3
Healthcare Sector # 11
Within the Market # 36


trailing twelve months Leverage Ratio Statistics
High Average Low
29.08 5.82 0.63
(Sep 30 2017)   (Sep 30 2019)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Equity
Halozyme Therapeutics Inc   19.68 $ 1,649.462  Millions$ 83.808  Millions
Amgen Inc   13.84 $ 86,242.000  Millions$ 6,232.000  Millions
Adaptimmune Therapeutics Plc  6.15 $ 243.103  Millions$ 39.513  Millions
Inhibrx Inc   6.00 $ 261.217  Millions$ 43.503  Millions
Pluri Inc   4.80 $ 31.762  Millions$ 6.617  Millions

Date modified: 2024-02-21T14:19:45+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com